Immutep

Phase I

image Immutep S.A. announced today that it has initiated a Phase I clinical trial of its lead product ImmuFact® IMP321 in metastatic renal cell carcinoma. This is the Company's first clinical trial targeting cancer. Immutep is already carrying out trials of IMP321 to show safety and immune response to infectious disease antigens in healthy volunteers. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response through activation of dendritic cells and more efficient antigen presentation to T cells.

Please, click on ADOBE PDF logo to read the complete communique.

Published 11/2005 by admin@immutep.com
» Office and Laboratory Leases
© 2002 Immutep, S.A.
Press Release
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate
image Immutep S.A. announced today interim results from the first three ...
09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells
image Immutep S.A. announced today the publication of a clinical research ...
04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO)
image Immutep S.A. announced today the first administration of IMP321 in ...